KiOmed Pharma and Hansoh Pharma Announce License Agreement for KiOmedinevsOne in China’s Mainland, Macau and Taiwan
Retrieved on:
Monday, September 26, 2022
Managed Care, Biotechnology, Pharmaceutical, Health, Knee, Central nervous system, Degenerative disease, Safety, KIOM-LP, Prevalence, NSCLC, Ophthalmology, NMOSD, Hyaluronic acid, Population, Human, Osteoarthritis, WOMAC, CML, Partnership, Diabetes, Neuromyelitis optica spectrum disorder, Patient, History, Physician, Oxidative stress, CEO, CE, Pain, Agaricus bisporus, BCR-ABL, Acute leukemia, Board, CNS, Research, Infection, NMPA, Chitosan, EGFR, View, SEHK, Stiffness, Pharmaceutical industry, Inebilizumab
Hansoh will receive exclusive rights to develop and commercialize KiOmedinevsOne and its future extensions in the territory.
Key Points:
- Hansoh will receive exclusive rights to develop and commercialize KiOmedinevsOne and its future extensions in the territory.
- KiOmed retains the right to develop and commercialize KiOmedinevsOne in all other global markets.
- We are very excited to partner with Hansoh Pharma, one of the largest biopharmaceutical entities in Greater China.
- We are very glad to see KiOmeds product (KiOmedinevsOne) will help to solve this problem, said Eliza Sun, Executive Director of the Board of Hansoh Pharma.